The global hemostasis testing systems market is poised for substantial growth, with a projected value surge from USD 2,149.3 million in 2023 to USD 3,666 million by 2033. This anticipated expansion is ...

Sanofi (SNY) intends to spend about $1.05B building a new insulin manufacturing base in China, Kimberley Kao of The Wall Street Journal ...

The Chinese government's policies promoting opening up and innovation, as well as the excellent business environment it fosters for foreign enterprises, have injected strong confidence into Sanofi's ...

French pharma giant Sanofi will invest some 1 billion euros ($1.05 billion) to establish a new insulin production base in ...

Sanofi a leading global healthcare company invests ampeuro1 billion in Beijing for a new insulin plant creating jobs and bolstering China health ...

Health-care companies ticked down, but remained near all-time highs, amid promising drug developments in the biotech niche. Janux Therapeutics stock surged after the California biotech concern's ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Sanofi’s latest capital outlay in China will cover the development of a new insulin plant in the nation’s capital.

Sanofi is one of the world's top producers of insulin, and the China market for treatment of the illness is huge: Some 140 ...

A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.

French drug major Sanofi plans to invest around 1 billion euros or about $1.05 billion to build a new insulin manufacturing base in ...

The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing ...